Wide Ranks

AMRX

Amneal Pharmaceuticals, Inc.

8.35

Top Statistics
Market Cap 3 B Forward PE 11.45 Revenue Growth 13.30 %
Current Ratio 1.38 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -6.88 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 9.20 Enterprise / Revenue 1.95 Price To Sales Trailing12 Months 1.44
Profitability
Profit Margins -6.88 % Operating Margins 12.50 %
Balance Sheet
Total Cash 77 M Total Cash Per Share 0.2490 Total Debt 2 B
Total Debt To Equity Current Ratio 1.38 Book Value Per Share -0.3020
All Measures
Short Ratio 412.00 % Message Board Id finmb_38444119 Fax 908 947 3146
Shares Short Prior Month 4 M Return On Equity -1.86 City Bridgewater
Uuid 0fcb03eb-c390-34ae-8733-d78649324217 Previous Close 8.25 First Trade Date Epoch Utc 1 B
Book Value -0.3020 Beta 1.18 Total Debt 2 B
Volume 976424 Fifty Two Week Low 4.17 Total Cash Per Share 0.2490
Total Revenue 2 B Shares Short Previous Month Date 1 B Target Median Price 10.50
Audit Risk 3 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Operating Margins 12.50 % Target Mean Price 10.50
Net Income To Common -184454000 Short Percent Of Float 0.0174 Implied Shares Outstanding 461 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 77 M Next Fiscal Year End 1 B
Revenue Per Share 9.16 Held Percent Insiders 0.5219 Ebitda Margins 21.14 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 4 Regular Market Previous Close 8.25 Target Low Price 9.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 8.54 Open 8.25
Free Cashflow 230 M State NJ Dividend Yield 0.00 %
Return On Assets 0.0594 Time Zone Short Name EST Board Risk 7
Trailing Eps -0.8600 Day Low 8.11 Address1 400 Crossing Boulevard
Shares Outstanding 309 M Compensation Risk 3 Price Hint 2
Target High Price 12.00 Website https://amneal.com 52 Week Change 0.9374
Average Volume 1 M Forward Eps 0.7100 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 78.80 % Is_sp_500 False
Regular Market Day High 8.37 Profit Margins -6.88 % Fifty Two Week High 9.47
Day High 8.37 Shares Short 4 M Regular Market Open 8.25
Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 % Enterprise To Revenue 1.95
Revenue Growth 13.30 % Shares Percent Shares Out 0.0145 Operating Cashflow 312 M
Currency USD Time Zone Full Name America/New_York Market Cap 3 B
Is_nasdaq_100 False Zip 08807 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Amneal Pharmaceuticals, Inc. Overall Risk 4
Regular Market Day Low 8.11 Held Percent Institutions 0.4627 Current Price 8.35
Address2 3rd Floor Enterprise To Ebitda 9.20 Financial Currency USD
Current Ratio 1.38 Gross Margins 36.53 % Industry Disp Drug Manufacturers - Specialty & Generic
Number Of Analyst Opinions 4 Country United States Float Shares 141 M
Two Hundred Day Average 7.18 Governance Epoch Date 1 B Enterprise Value 5 B
Price To Sales Trailing12 Months 1.44 Forward PE 11.45 Regular Market Volume 976424
Ebitda 566 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

The company operates through three segments: Generics, Specialty, and AvKARE.

The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders.

This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease.

The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.

This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.

It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.

The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018.

Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.